Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.35 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526988 | 0.97 | MPI (0.37) | MPIBTN3A1LMNAL3MBTL1TDP1 | |
| SCHEMBL18486548 | 0.95 | LMNA (0.34) | MPIBTN3A1LMNAL3MBTL1TDP1 | |
| SCHEMBL18486485 | 0.95 | LMNA (0.34) | MPIBTN3A1LMNAL3MBTL1TDP1 | |
| Phosphoric Acid SCHEMBL19583205 | 0.95 | MPI (0.36) | MPIBTN3A1LMNAL3MBTL1TDP1 | |
| SCHEMBL5165444 | 0.92 | LMNA (0.37) | MPIBTN3A1LMNAL3MBTL1TDP1 | |
| SCHEMBL536484 | 0.92 | LMNA (0.37) | MPIBTN3A1LMNAL3MBTL1TDP1 | |
| SCHEMBL3687102 | 0.92 | LMNA (0.37) | MPIBTN3A1LMNAL3MBTL1TDP1 | |
| SCHEMBL4082207 | 0.92 | LMNA (0.37) | MPIBTN3A1LMNAL3MBTL1TDP1 | |
| SCHEMBL8155983 | 0.90 | LMNA (0.35) | MPIBTN3A1LMNAL3MBTL1TDP1 | |
| SCHEMBL30679812 | 0.88 | MPI (0.33) | MPIBTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271968-A | Chemical mechanical polishing solution | 安集微电子科技（上海）股份有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-116515398-A | Chemical mechanical polishing solution and application method thereof | 安集微电子（上海）有限公司 | 2023-08-01 | — | — | CN | claimed |
| CN-114907272-A | Bivalent nucleobase compound and use thereof | 卡耐基梅隆大学 | 2022-08-16 | — | — | CN | claimed |
| CN-114716915-A | Chemical mechanical polishing solution | 安集微电子科技（上海）股份有限公司 | 2022-07-08 | — | — | CN | claimed |
| US-20220096468-A1 | Therapeutic agent for RNA viral infection comprising a combination of pyrazine derivative and compound which increases amount of pyrazine derivative ribose triphosphate in cell | FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP) | 2022-03-31 | — | — | US | claimed |
| EP-3903783-A1 | THERAPEUTIC AGENT FOR RNA VIRAL INFECTION OBTAINED BY COMBINING PYRAZINE DERIVATIVE AND COMPOUND INCREASING AMOUNT OF PYRAZINE DERIVATIVE RIBOSE TRIPHOSPHATE BODIES IN CELL | FUJIFILM Toyama Chemical Co., Ltd. (JP) | 2021-11-03 | — | — | EP | claimed |
| WO-2020138067-A1 | THERAPEUTIC AGENT FOR RNA VIRAL INFECTION OBTAINED BY COMBINING PYRAZINE DERIVATIVE AND COMPOUND INCREASING AMOUNT OF PYRAZINE DERIVATIVE RIBOSE TRIPHOSPHATE BODIES IN CELL | 富士フイルム富山化学株式会社 | 2020-07-02 | — | — | WO | claimed |
| EP-4731762-A2 | DE NOVO STEPWISE TEMPLATE-INDEPENDENT SYNTHESIS OF LONG POLYNUCLEOTIDES | Ansa Biotechnologies, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-3727435-B1 | BIVALENT NUCLEIC ACID LIGANDS AND USES THEREFOR | UNIV CARNEGIE MELLON (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12428659-B2 | De novo polynucleotide synthesis with substrate-bound polymerase | MICROSOFT TECHNOLOGY LICENSING, LLC (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250283136-A1 | SPATIALLY ADDRESSABLE CONTROL OF POLYMERASE ACTIVITY | MICROSOFT TECHNOLOGY LICENSING, LLC | 2025-09-11 | — | — | US | disclosed |
| US-12344876-B2 | Spatially addressable control of polymerase activity | MICROSOFT TECHNOLOGY LICENSING, LLC (US) | 2025-07-01 | — | — | US | disclosed |
| US-12297231-B2 | Shape-responsive nanostructures | CARNEGIE MELLON UNIVERSITY (US) | 2025-05-13 | — | — | US | disclosed |
| US-5763167-A | Applications of fluorescent N-nucleosides and fluorescent structural analogs of N-nucleosides | CHROMAGEN (US) | 1998-06-09 | — | — | US | disclosed |
| US-5728525-A | RNA AND DNA WITH FLUORESCENT GROUPS FORMED BY ENZYME OR CHEMICAL SYNTHESIS | CHROMAGEN, INC. (US) | 1998-03-17 | — | — | US | disclosed |
| US-5652099-A | FOR USE IN SYNTHESIS OF FLUORESCENT OLIGONUCLEOTIDES | CONRAD MICHAEL J (US) | 1997-07-29 | — | — | US | disclosed |
| EP-0669928-A1 | APPLICATIONS OF FLUORESCENT N-NUCLEOSIDES AND FLUORESCENT STRUCTURAL ANALOGS OF N-NUCLEOSIDES | CHROMAGEN, INC. (US) | 1995-09-06 | — | — | EP | disclosed |
| WO-1995005391-A1 | APPLICATIONS OF FLUORESCENT N-NUCLEOSIDES AND FLUORESCENT STRUCTURAL ANALOGS OF N-NUCLEOSIDES | CHROMAGEN, INC. (US) | 1995-02-23 | — | — | WO | disclosed |
| EP-0628051-A1 | APPLICATIONS OF FLUORESCENT N-NUCLEOSIDES AND FLUORESCENT STRUCTURAL ANALOGS OF N-NUCLEOSIDES | CHROMAGEN, INC. (US) | 1994-12-14 | — | — | EP | disclosed |
| WO-1993016094-A2 | APPLICATIONS OF FLUORESCENT N-NUCLEOSIDES AND FLUORESCENT STRUCTURAL ANALOGS OF N-NUCLEOSIDES | CHROMAGEN, INC. (US) | 1993-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096468-A1 | Therapeutic agent for RNA viral infection comprising a combination of pyrazine derivative and compound which increases amount of pyrazine derivative ribose triphosphate in cell | EIF2AK2, NSUN2, ZC3HAV1 | MPI 806/4885BTN3A1 4263/4885LMNA 4361/4885 |
| US-12297231-B2 | Shape-responsive nanostructures | SSTR1, SSTR4, SSTR3 | MPI 1027/4885BTN3A1 208/4885LMNA 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.